![Quiver Logo](/static/img/logo-icon.png)
![VYNE logo](https://quiver-logos.s3.us-east-2.amazonaws.com/vyne.png)
VYNE Therapeutics Inc. Common Stock
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VYNE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of VYNE by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VYNE's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to VYNE
Recent picks made for VYNE stock on CNBC
ETFs with the largest estimated holdings in VYNE
Flights by private jets registered to VYNE
![Quiver Logo](/static/img/logo-icon.png)